Challenge in Predicting Persistence to P2Y12 Inhibitors: A Perspective From the ARTEMIS Trial

BACKGROUND: Premature discontinuation of P2Y12 inhibitor therapy has been associated with adverse cardiac events, which might be preventable by improving medication persistence. Current risk models have limited ability to predict patients at risk of P2Y12 inhibitor nonpersistence. METHODS AND RESULT...

Descripción completa

Detalles Bibliográficos
Autores principales: Rymer, Jennifer A., Wegermann, Zachary K., Kaltenbach, Lisa A., Webb, Laura E., Peterson, Eric D., Wang, Tracy Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356056/
https://www.ncbi.nlm.nih.gov/pubmed/37301758
http://dx.doi.org/10.1161/JAHA.122.029063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356056/
https://www.ncbi.nlm.nih.gov/pubmed/37301758
http://dx.doi.org/10.1161/JAHA.122.029063

Ejemplares similares